Evidence map›Paper›PMID 29398134›Full record

GuidelineKidney international2018

Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Charles R Swanepoel, Mohamed G Atta, Vivette D D'Agati, Michelle M Estrella, Agnes B Fogo, Saraladevi Naicker, Frank A Post, Nicola Wearne, Cheryl A Winkler, Michael Cheung and 4 more

Open access · bronzeAbstract readConsensus StatementPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Kidney international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 6 pooled it
23.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 6 syntheses or guidelines pooled it, 235 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 3 countries.

Charles R SwanepoelDivision of Nephrology and Hypertension, University of Cape Town, Cape Town, South Africa. Electronic address: charles.swanepoel@uct.ac.za.
Mohamed G AttaDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Vivette D D'AgatiDepartment of Pathology & Cell Biology, Columbia University Medical Center, New York, New York, USA.
Michelle M EstrellaDepartment of Medicine, San Francisco VA Medical Center and University of California, San Francisco, California, USA.
Agnes B FogoDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee, USA.
Saraladevi NaickerDepartment of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Frank A PostKing's College Hospital NHS Foundation Trust, London, UK.
Nicola WearneDivision of Nephrology and Hypertension, University of Cape Town, Cape Town, South Africa.
Cheryl A WinklerBasic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health and Leidos Biomedical Research, Frederick National Laboratory, Frederick, Maryland, USA.
Michael CheungKDIGO, Brussels, Belgium.
David C WheelerUniversity College London, London, UK.
Wolfgang C WinkelmayerSelzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Christina M WyattDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: christina.wyatt@mssm.edu.
Conference Participants
University of Cape Town · ZABaylor College of Medicine · USColumbia University Irving Medical Center · USIcahn School of Medicine at Mount Sinai · USJohns Hopkins Medicine · USKing's College Hospital NHS Foundation Trust · GBLeidos Biomedical Research Inc. (United States)University College London · GBUniversity of California, San Francisco · USUniversity of the Witwatersrand · ZAVanderbilt University · US

Funding

VIRAL PATHOGENESIS OF HIV ASSOCIATED NEPHROPATHYP01DK056492 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI KLOTMAN, MARY E. · 1999 to 2021
$27.8M
Role of bFGF low affinity receptors in childhood HIVANR01DK049419 · NIDDK · UNIVERSITY OF VIRGINIA · PI PATRICIO E. RAY · 1994 to 2026
$7.4M
Identification of Genetic Factors Associated with Infectious DiseasesZIABC010297 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WINKLER, CHERYL · 2009 to 2022
$6.3M
Incidence and Implications of Subclinical Kidney Injury with Tenofovir based PrEPR01DK100272 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WYATT, CHRISTINA M · 2014 to 2016
$1.8M
Pathogenesis of chronic renal injury and hypertension in HIV-infected childrenR01DK108368 · NIDDK · UNIVERSITY OF VIRGINIA · PI RAY, PATRICIO E. · 2015 to 2019
$1.5M
NIDDK NIH HHS P01 DK056492NIDDK NIH HHS R01 DK049419NIDDK NIH HHS R01 DK100272NIDDK NIH HHS R01 DK108368
6 · The paper itself

Abstract

HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.

Indexed as

AIDS-Associated NephropathyHIVKidneyRenal Insufficiency, ChronicAnti-HIV AgentsComorbidityDiagnosis, DifferentialEvidence-Based MedicineGenetic Predisposition to DiseaseHost-Pathogen InteractionsHumansNephrologyPredictive Value of TestsRisk FactorsTreatment OutcomeAnti-HIV Agentsantiretroviral therapyAPOL1CKD progressionHIVimmune complex kidney diseasepodocytopathyrenal pathology

Identifiers

PMID29398134
PMCPMC5983378
OpenAlexW2768442939

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.